Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock - $0.001 par value
-
Shares outstanding
-
127,940,509
-
Total 13F shares
-
47,595,247
-
Share change
-
+12,546,162
-
Total reported value
-
$513,251,453
-
Price per share
-
$10.78
-
Number of holders
-
71
-
Value change
-
+$121,245,207
-
Number of buys
-
59
-
Number of sells
-
16
Institutional Holders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) as of Q1 2022
As of 31 Mar 2022,
Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) was held by
71 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
47,595,247 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., HHLR ADVISORS, LTD., VANGUARD GROUP INC, BlackRock Inc., Miura Global Management, LLC, STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, D. E. Shaw & Co., Inc., NORTHERN TRUST CORP, and GOLDMAN SACHS GROUP INC.
This page lists
71
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.